Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Acta Oncol. 2024 May 28;63:411-417. doi: 10.2340/1651-226X.2024.32745.
In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST.
PATIENTS/MATERIAL AND METHODS: MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies.
PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.
在本手稿中，我们描述了学术性法国多中心分子分析平台，包括由里昂·贝拉德中心推动的 PROFILER，以及多中心个体化医学试验 MOST、MOST Plus 和 MEGAMOST。
患者/材料与方法：MOST、MOST Plus 和 MEGAMOST 包括 14 个具有不同靶向药物和免疫疗法的队列。
PROFILER 在 10 年内招募了 5991 名患者，MOST 和 MOST Plus 自 2014 年以来招募了 875 名患者，MEGAMOST 自 2020 年以来招募了 172 名患者，目前仍在进行中。我们提供了对这些举措的地方、国家和国际影响的描述，并回顾了索拉非尼和奥拉帕利队列的结果。
